

# Prism Medico & Pharmacy Limited

CIN: L51109PB2002PLC047444

D-118, INDUSTRIAL AREA,  
PHASE VII, MOHALI-160055

Telephone no – 0172-5020762

Email Id –investorgrievancewmcl@gmail.com

Date: 14/02/2019

|  |  |
|--|--|
| To,<br>Department of Corporate Services,<br>BSE Limited<br>P.J. Towers, Dalal Street,<br>Mumbai – 400 001. | To,<br>Listing Department,<br><b>Metropolitan Stock Exchange of India<br/>Ltd. (MSE)</b><br>Vibgyor Towers, 4th floor,<br>Plot No C 62, G - Block,<br>Opp. Trident Hotel,<br>Bandra Kurla Complex,<br>Bandra (E), Mumbai – 400 098, India.<br><br><b>ISIN : INE730E01016</b><br><b>SYMBOL: PRISMMEDI</b> |
| <b>Scip Code: 512217</b>   |  |

**Subject: Outcome of Board Meeting held on Thursday, 14<sup>th</sup> February, 2019**

Dear Sir/Madam


Pursuant to the provisions of Regulation 30(2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform your good self that the Board of Directors in their meeting held on **Thursday, 14<sup>th</sup> February, 2019 at 4.00 p.m. and concluded at 4:30 p.m. :**

1. Considered and Approved and taken on records the Unaudited Financial results along with the Limited Review Report for the quarter ended on 31<sup>st</sup> December, 2018 (standalone and consolidated) as recommended by the Audit Committee. Further, we hereby enclose the following:
  - a. Unaudited Financial Results for the quarter ended 31<sup>st</sup> December, 2018.
  - b. Limited Review Report received from the Statutory Auditor of the Company.

You are requested to take the same on record and acknowledge receipt.

Thanking You,

For **PRISM MEDICO & PHARMACY LIMITED**  
For Prism Medico & Pharmacy Ltd.

  
**Gursimran Singh** Director  
**DIRECTOR**  
**DIN: 02209675**

# PRISM MEDICO AND PHARMACY LTD.

CIN : L51109PB2002PLCO47444

## STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2018 (IN LAKHS)

| PARTICULARS  | Quarter Ended (Unaudited) |                |               | Year Ended<br>(Audited) |
|--|---------------------------|----------------|---------------|-------------------------|
|  | 31.12.2018                | 30.09.2018     | 31.12.2017    | 31.03.2018              |
| <b>1 INCOME FROM OPERATIONS</b>  |                           |                |               |                         |
| A Net Sales/ Income From Operations  | 1711.28                   | 1500.36        | 472.29        | 2280.22                 |
| B Other Operating Income   | 2.10                      | 0.33           | 0.15          | 0.00                    |
| <b>TOTAL INCOME FROM OPERATIONS (NET)</b>  | <b>1713.38</b>            | <b>1500.69</b> | <b>472.44</b> | <b>2280.22</b>          |
| <b>2 EXPENSES:</b>   |                           |                |               |                         |
| Cost of Material Consumed  | 0.00                      | 0.00           | -2.31         | 0.00                    |
| Purchase of Stock-In-Trade   | 1409.70                   | 1935.26        | 570.98        | 1948.16                 |
| Change In Inventories  | 248.26                    | -491.10        | -111.60       | 179.84                  |
| Employee Benefit Expenses  | 9.19                      | 3.91           | 3.25          | 21.06                   |
| Payment to BSE   | 0.00                      | 1.80           | 0.00          | 2.88                    |
| Depreciation   | 6.73                      | 6.73           | 11.90         | 44.65                   |
| Other Expenses (Any Item Exceeding 10% of Other Expenses Relating To Continuing Operations To Be Shown Separately)       | 21.95                     | 18.88          | 4.33          | 52.21                   |
| <b>TOTAL EXPENSES</b>  | <b>1695.82</b>            | <b>1475.49</b> | <b>476.56</b> | <b>2248.80</b>          |
| <b>3 PROFIT / (LOSS) FROM OPERATION BEFORE OTHER INCOME, FINANCE COST AND EXCEPTIONAL ITEMS (1-2)</b>                    | <b>17.56</b>              | <b>25.21</b>   | <b>-4.13</b>  | <b>31.42</b>            |
| 4 Other Income   |                           | 5.45           |               | 4.26                    |
| <b>5 PROFIT / (LOSS) FROM ORDINARY ACTIVITIES BEFORE FINANCE COST AND EXCEPTIONAL ITEMS (3 + 4)</b>                      | <b>17.56</b>              | <b>30.66</b>   | <b>-4.13</b>  | <b>35.68</b>            |
| 6 Finance Cost   | 2.85                      | 2.91           | 7.51          | 28.87                   |
| <b>7 PROFIT / (LOSS) FROM ORDINARY ACTIVITIES AFTER FINANCE COST BUT BEFORE EXCEPTIONAL ITEMS (5 + 6)</b>                | <b>14.71</b>              | <b>27.74</b>   | <b>-11.64</b> | <b>6.81</b>             |
| 8 Exceptional Items  | 0.00                      | 0.00           |               | 0.00                    |
| <b>9 PROFIT / (LOSS) FROM ORDINARY ACTIVITIES BEFORE TAX (7 + 8)</b>   | <b>14.71</b>              | <b>27.74</b>   | <b>-11.64</b> | <b>6.81</b>             |
| <b>10 TAX EXPENSE:</b>   |                           |                |               |                         |
| (1) Current Tax  | 0.00                      | 0.00           | 0.00          | 1.30                    |
| (2) Deferred Tax   | 0.00                      | 0.00           | 0.00          | 7.22                    |
| (3) MAT Credit   | 0.00                      | 0.00           | 0.00          | 1.30                    |
| <b>11 NET PROFIT / (LOSS) FROM ORDINARY ACTIVITIES AFTER TAX (9+10)</b>  | <b>14.71</b>              | <b>27.74</b>   | <b>-11.64</b> | <b>** -0.41</b>         |
| 12 Extraordinary Items (Net of Tax Expense ___ Lakhs)  | 0.00                      | 0.00           |               | 0.00                    |
| <b>13 NET PROFIT / (LOSS) FOR THE PERIOD (11 + 12)</b>   | <b>14.71</b>              | <b>27.74</b>   | <b>-11.64</b> | <b>-0.41</b>            |
| 14 Share of Profit / (loss) of associates *  | 0.00                      | 0.00           | 0.00          | 0.00                    |
| 15 Minority Interest *   | 0.00                      | 0.00           | 0.00          | 0.00                    |
| <b>16 NET PROFIT / (LOSS) AFTER TAXES, MINORITY INTEREST AND SHARE OF PROFIT / (LOSS) OF ASSOCIATES (13 + 14 + 15) *</b> | <b>14.71</b>              | <b>27.74</b>   | <b>-11.64</b> | <b>-0.41</b>            |
| 17 Paid-up equity share capital (Face Value of the Share shall be indicated)   | 606.34                    | 606.34         | 606.34        | 606.34                  |
| 18 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year                               | 680.84                    | 680.84         | 681.25        | 681.25                  |

For Prism Medico & Pharmacy Ltd.

*Gurjinder Singh*

Director

|  |            |      |      |       |       |
|--|------------|------|------|-------|-------|
| Earnings Per Share (before extraordinary items) (of Rs ___/- each) (not annualised): |            |      |      |       |       |
| 19   | (1)BASIC   | 0.24 | 0.46 | -0.19 | -0.01 |
|  | (2)DILUTED | 0.24 | 0.46 | -0.19 | -0.01 |
| Earnings Per Share (after extraordinary items) (of Rs ___/- each) (not annualised):  |            |      |      |       |       |
| 19   | (1)BASIC   | 0.24 | 0.46 | -0.19 | -0.01 |
|  | (2)DILUTED | 0.24 | 0.46 | -0.19 | -0.01 |

\* Applicable in the case of consolidated results.

**Notes:**

1. The above Unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 14TH February, 2019.
2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning April 1, 2017, the Company has for the first time adopted Ind AS with a transition date of April 1, 2017.
3. The company is having single segment in accordance with IND AS 108 "operating segments". and therefore segment reporting is not applicable to the Company.

**FOR & ON BEHALF OF THE BOARD  
PRISM MEDICO AND PHARMACY LTD.**

*For Prism Medico & Pharmacy Ltd.*

*Gursimran Singh* Director

**Director**

**DIN: 02209675**

Place : Mohali

Date : 14.02.2019



**PRISM MEDICO AND PHARMACY LTD.**

CIN : L51109PB2002PLC047444

**CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES AS ON 31st DECEMBER, 2018**

| CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES | AS ON          | AS ON          |
|--|----------------|----------------|
|  | 31.12.2018     | 31.03.2018     |
| <b>I.EQUITY AND LIABILITIES</b>                  |                |                |
| <b>(1) SHAREHOLDER'S FUND</b>                    |                |                |
| (A) SHARE CAPITAL                                | 606.34         | 606.34         |
| (B) RESERVES AND SURPLUS                         | 746.50         | 680.84         |
| (C) MONEY RECEIVED AGAINST SHARE WARRANTS        | -              | -              |
| <b>SUB-TOTAL - SHAREHOLDERS' FUNDS</b>           | <b>1352.84</b> | <b>1287.19</b> |
| (2) SHARE APPLICATION MONEY PENDING ALLOTMENT    | -              | -              |
| (3) MINORITY INTEREST *                          | -              | -              |
| <b>(4) NON CURRENT LIABILITIES</b>               |                |                |
| (A) LONG TERM BORROWINGS                         | 52.31          | 91.54          |
| (B) DEFERRED TAX LIABILITIES (NET)               | 7.49           | 7.49           |
| (C) OTHER NON-CURRENT LIABILITIES                | 2.50           | 2.50           |
| (D) LONG-TERM PROVISIONS                         | -              | -              |
| <b>SUB-TOTAL - NON-CURRENT LIABILITIES</b>       | <b>62.30</b>   | <b>101.53</b>  |
| <b>(5) CURRENT LIABILITIES</b>                   |                |                |
| (A) SHORT TERM BORROWINGS                        | 115.33         | 125.16         |
| (B) TRADE PAYABLE                                | 993.53         | 53.06          |
| (C) OTHER CURRENT LIABILITIES                    | 10.76          | 11.72          |
| (D) SHORT TERM PROVISIONS                        | 0.05           | 1.30           |
| <b>SUB-TOTAL - CURRENT LIABILITIES</b>           | <b>1119.66</b> | <b>191.23</b>  |
| <b>TOTAL EQUITY &amp; LIABILITIES</b>            | <b>2534.80</b> | <b>1579.95</b> |
| <b>II.ASSETS</b>                                 |                |                |
| <b>(1) NON CURRENT ASSETS</b>                    |                |                |
| (A) FIXED ASSETS                                 |                |                |
| (i) TANGIBLE ASSETS                              | 910.46         | 930.65         |
| (B) GOODWILL ON CONSOLIDATION *                  | 0.00           | 0.00           |
| (C) NON CURRENT INVESTMENTS                      | 260.72         | 260.72         |
| (D) DEFERRED TAX ASSETS (NET)                    | 0.00           | 0.00           |
| (E) LONG TERM LOANS & ADVANCES                   | 2.30           | 2.30           |
| (F) OTHER NON CURRENT ASSETS                     | 0.00           | 0.00           |
| <b>SUB-TOTAL - NON-CURRENT ASSETS</b>            | <b>1173.47</b> | <b>1193.66</b> |
| <b>(2) CURRENT ASSETS</b>                        |                |                |
| (A) CURRENT INVESTMENTS                          |                |                |
| (B) INVENTORIES                                  | 125.61         | 149.10         |
| (C) TRADE RECEIVABLES                            | 944.61         | 0.00           |
| (D) CASH AND CASH EQUIVALENTS                    | 94.56          | 135.82         |
| (E) SHORT TERM LOANS AND ADVANCES                | 192.88         | 96.01          |
| (F) OTHER CURRENT ASSETS                         | 3.66           | 5.36           |
| <b>SUB-TOTAL - CURRENT ASSETS</b>                | <b>1361.32</b> | <b>386.29</b>  |
| <b>TOTAL-ASSETS</b>                              | <b>2534.80</b> | <b>1579.95</b> |

\*APPLICABLE IN THE CASE OF CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES

FOR & ON BEHALF OF THE BOARD  
PRISM MEDICO AND PHARMACY LTD.  
For Prism Medico & Pharmacy Ltd.

*Gursimran Sp*  
**Gursimran Singh**  
Director  
DIN: 02209675

Place : Mohali  
Date : 14.02.2019

# PRISM MEDICO AND PHARMACY LTD.

CIN : L51109PB2002PLC047444

## STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2018 (IN LAKHS)

| #  | PARTICULARS   | Quarter Ended (Unaudited) |               |               | Year Ended (Audited) |
|----|---|---------------------------|---------------|---------------|----------------------|
|    |   | 31.12.2018                | 30.09.2018    | 31.12.2017    | 31.03.2018           |
| 1  | <b>INCOME FROM OPERATIONS</b>   |                           |               |               |                      |
|    | A Net Sales/ Income From Operations   | 1174.94                   | 865.55        | 518.87        | 2095.81              |
|    | B Other Operating Income  | 0.00                      | 0.00          | 0.00          | 0.00                 |
|    | <b>TOTAL INCOME FROM OPERATIONS (NET)*</b>  | <b>1174.94</b>            | <b>865.55</b> | <b>518.87</b> | <b>2095.81</b>       |
| 2  | <b>EXPENSES:</b>  |                           |               |               |                      |
|    | Cost of Material Consumed   | 0.00                      | 0.00          |               | 0.00                 |
|    | Purchase of Stock-In-Trade  | 866.11                    | 1316.62       | 623.29        | 2072.70              |
|    | Change In Inventories   | 248.23                    | -501.19       | -111.60       | -9.55                |
|    | Employee Benefit Expenses   | 9.19                      | 3.91          | 0.90          | 9.54                 |
|    | Payment to BSE  | 0.00                      | 1.80          | 0.00          | 2.88                 |
|    | Depreciation  | 0.67                      | 0.67          | 0.49          | 4.46                 |
|    | Other Expenses (Any Item Exceeding 10% of Other Expenses Relating To Continuing Operations To Be Shown Separately)    | 21.81                     | 18.24         | 1.58          | 11.10                |
|    | <b>TOTAL EXPENSES</b>   | <b>1146.00</b>            | <b>840.04</b> | <b>514.67</b> | <b>2091.13</b>       |
|    | <b>PROFIT / (LOSS) FROM OPERATION BEFORE OTHER INCOME, FINANCE COST AND EXCEPTIONAL ITEMS (1-2)</b>                   | <b>28.94</b>              | <b>25.51</b>  | <b>4.20</b>   | <b>4.68</b>          |
| 3  |   |                           |               |               |                      |
| 4  | Other Income  | 0.00                      | 0.00          | 0.00          | 0.00                 |
|    | <b>PROFIT / (LOSS) FROM ORDINARY ACTIVITIES BEFORE FINANCE COST AND EXCEPTIONAL ITEMS (3 + 4)</b>                     | <b>28.94</b>              | <b>25.51</b>  | <b>4.20</b>   | <b>4.68</b>          |
| 5  |   |                           |               |               |                      |
| 6  | Finance Cost  | 0.01                      | 0.01          | 0.01          | 0.02                 |
|    | <b>PROFIT / (LOSS) FROM ORDINARY ACTIVITIES AFTER FINANCE COST BUT BEFORE EXCEPTIONAL ITEMS (5 + 6)</b>               | <b>28.94</b>              | <b>25.50</b>  | <b>4.19</b>   | <b>4.66</b>          |
| 7  |   |                           |               |               |                      |
| 8  | Exceptional Items   | 0.00                      | 0.00          | 0.00          | 0.00                 |
|    | <b>PROFIT / (LOSS) FROM ORDINARY ACTIVITIES BEFORE TAX (7 + 8)</b>  | <b>28.94</b>              | <b>25.50</b>  | <b>4.19</b>   | <b>4.66</b>          |
| 9  |   |                           |               |               |                      |
| 10 | <b>TAX EXPENSE:</b>   |                           |               |               |                      |
|    | (1) Current Tax   | 0.00                      | 0.00          | 0.00          | 0.89                 |
|    | (2) Deferred Tax  | 0.00                      | 0.00          | 0.00          | 6.56                 |
|    | (3) MAT Credit  | 0.00                      | 0.00          | 0.00          | 0.89                 |
| 11 | <b>NET PROFIT / (LOSS) FROM ORDINARY ACTIVITIES AFTER TAX (9+10)</b>  | <b>28.94</b>              | <b>25.50</b>  | <b>4.19</b>   | <b>-1.89</b>         |
| 12 | Extraordinary Items (Net of Tax ` Expense ___ Lakhs)  |                           | 0.00          | 0.00          | 0.00                 |
| 13 | <b>NET PROFIT / (LOSS) FOR THE PERIOD (11 + 12)</b>   | <b>28.94</b>              | <b>25.50</b>  | <b>4.19</b>   | <b>-1.89</b>         |
| 14 | Share of Profit / (loss) of associates *  | 0.00                      | 0.00          | 0.00          | 0.00                 |
| 15 | Minority Interest *   | 0.00                      | 0.00          | 0.00          | 0.00                 |
| 16 | <b>NET PROFIT / (LOSS) AFTER TAXES, MINORITY INTEREST AND SHARE OF PROFIT / (LOSS) OF ASSOCIATES (13 + 14 + 15) *</b> | <b>28.94</b>              | <b>25.50</b>  | <b>4.19</b>   | <b>-1.89</b>         |

For Prism Medico & Pharmacy Ltd.

*(Signature)*  
Prism Medico & Pharmacy Ltd.

Director



|    |   |        |        |        |        |
|----|---|--------|--------|--------|--------|
| 17 | Paid-up equity share capital (Face Value of the Share shall be indicated)               | 606.34 | 606.34 | 606.34 | 606.34 |
| 18 | Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year | 718.81 | 718.81 | 673.69 | 673.69 |
| 19 | Earnings Per Share (before extraordinary items) (of Rs ___/- each) (not annualised):    |        |        |        |        |
|    | (1)BASIC  | 0.48   | 0.42   | 0.07   | -0.03  |
|    | (2)DILUTED  | 0.48   | 0.42   | 0.07   | -0.03  |
|    | Earnings Per Share (after extraordinary items) (of Rs ___/- each) (not annualised):     |        |        |        |        |
|    | (1)BASIC  | 0.48   | 0.42   | 0.07   | -0.03  |
|    | (2)DILUTED  | 0.48   | 0.42   | 0.07   | -0.03  |

\* Applicable in the case of consolidated results.

**Notes:**

- The above Unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 14TH February, 2019
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning April 1, 2017, the Company has for the first time adopted Ind AS with a transition date of April 1, 2017.
- The company is having single segment in accordance with IND AS 108 "operating segments". and therefore segment reporting is not applicable to the Company.

**FOR & ON BEHALF OF THE BOARD  
PRISM MEDICO AND PHARMACY LTD.**

For Prism Medico & Pharmacy Ltd.

*Gursimran Singh*  
**Gursimran Singh** Director

**Director**

**DIN: 02209675**

Place : Mohali

Date : 14.02.2019

**PRISM MEDICO AND PHARMACY LTD.**

CIN : L51109PB2002PLCO47444

**STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS ON 31st DECEMBER, 2018**

| CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES | AS ON          | AS ON          |
|--|----------------|----------------|
|  | 31.12.2018     | 31.03.2018     |
| <b>I. EQUITY AND LIABILITIES</b>                 |                |                |
| <b>(1) SHAREHOLDER'S FUND</b>                    |                |                |
| (A) SHARE CAPITAL                                | 606.34         | 606.34         |
| (B) RESERVES AND SURPLUS                         | 747.75         | 671.80         |
| (C) MONEY RECEIVED AGAINST SHARE WARRANTS        | 0.00           | 0.00           |
| <b>SUB-TOTAL - SHAREHOLDERS' FUNDS</b>           | <b>1354.09</b> | <b>1278.14</b> |
| (2) SHARE APPLICATION MONEY PENDING ALLOTMENT    | 0.00           | 0.00           |
| (3) MINORITY INTEREST *                          | 0.00           | 0.00           |
| <b>(4) NON CURRENT LIABILITIES</b>               | <b>0.00</b>    | <b>0.00</b>    |
| (A) LONG TERM BORROWINGS                         | 0.00           | 0.00           |
| (B) DEFERRED TAX LIABILITIES (NET)               | 6.74           | 6.74           |
| (C) OTHER NON-CURRENT LIABILITIES                | 0.00           | 0.00           |
| (D) LONG-TERM PROVISIONS                         | 0.00           | 0.00           |
| <b>SUB-TOTAL - NON-CURRENT LIABILITIES</b>       | <b>6.74</b>    | <b>6.74</b>    |
| <b>(5) CURRENT LIABILITIES</b>                   |                |                |
| (A) SHORT TERM BORROWINGS                        | 0.00           | 0.00           |
| (B) TRADE PAYABLE                                | 604.32         | 0.00           |
| (C) OTHER CURRENT LIABILITIES                    | 10.61          | 7.89           |
| (D) SHORT TERM PROVISIONS                        | 0.05           | 0.89           |
| <b>SUB-TOTAL - CURRENT LIABILITIES</b>           | <b>614.98</b>  | <b>8.78</b>    |
| <b>TOTAL EQUITY &amp; LIABILITIES</b>            | <b>1975.81</b> | <b>1293.67</b> |
| <b>II. ASSETS</b>                                |                |                |
| <b>(1) NON CURRENT ASSETS</b>                    |                |                |
| (A) FIXED ASSETS                                 |                |                |
| (i) TANGIBLE ASSETS                              | 9.20           | 11.21          |
| (B) GOODWILL ON CONSOLIDATION *                  | 0.00           | 0.00           |
| (C) NON CURRENT INVESTMENTS                      | 1125.00        | 1125.00        |
| (D) DEFERRED TAX ASSETS (NET)                    | 0.00           | 0.00           |
| (E) LONG TERM LOANS & ADVANCES                   | 0.00           | 0.00           |
| (F) OTHER NON CURRENT ASSETS                     | 0.00           | 0.00           |
| <b>SUB-TOTAL - NON-CURRENT ASSETS</b>            | <b>1134.20</b> | <b>1136.20</b> |
| <b>(2) CURRENT ASSETS</b>                        |                |                |
| (A) CURRENT INVESTMENTS                          | 0.00           | 0.00           |
| (B) INVENTORIES                                  | 82.97          | 88.55          |
| (C) TRADE RECEIVABLES                            | 625.44         | 0.00           |
| (D) CASH AND CASH EQUIVALENTS                    | 60.49          | 4.02           |
| (E) SHORT TERM LOANS AND ADVANCES                | 71.82          | 64.01          |
| (F) OTHER CURRENT ASSETS                         | 0.89           | 0.89           |
| <b>SUB-TOTAL - CURRENT ASSETS</b>                | <b>841.60</b>  | <b>157.46</b>  |
| <b>TOTAL-ASSETS</b>                              | <b>1975.81</b> | <b>1293.67</b> |

\*APPLICABLE IN THE CASE OF CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES

Place : Mohali  
Date : 14.02.2019

FOR & ON BEHALF OF THE BOARD  
PRISM MEDICO AND PHARMACY LTD.  
For Prism Medico & Pharmacy Ltd.  
*Gursimran (sp)*  
**Gursimran Singh** Director  
Director  
DIN: 02209675